Crescent Biopharma (CBIO) Guggenheim Securities 2nd Annual Healthcare Innovation Conference summary

Strategic vision and pipeline development

• Pursuing a dual strategy with a PD1 VEGF bispecific (CR001) and an internal ADC pipeline to build a leading oncology company.

• CR001 is designed as a next-generation IO backbone therapy, aiming to replace current standards and enter the clinic dosing patients in early Q1 next year.

• ADC 002 is expected to enter the clinic by mid-next year, with two clinical-stage assets anticipated by end of 2026 and robust data flow in 2027.

• The company emphasizes differentiation through molecule design and a dual approach, positioning itself at the early stage of a long-term market opportunity.

• Strong IP position and freedom to operate have been validated through IPO diligence and investor scrutiny.

Clinical development and trial design

• Phase I global trial for CR001 will start dosing in early Q1, focusing on safety, tolerability, PK/PD, and preliminary anti-tumor activity.

• The trial will address translation of Asian to Western data and inform registration trial design, dose selection, and tumor type prioritization.

• Initial focus will be on previously treated populations, with plans to expand into earlier lines and combination therapies.

• Emphasis on robust dose escalation and quality data to accelerate transition to later-stage studies and combinations.

Competitive landscape and indication strategy

• The PD1 VEGF space is highly competitive, with significant market potential and room for multiple players.

• Lung cancer remains a key target, with potential to be second or third to market in monotherapy, and additional indications under consideration.

• Phase I will include select indications, with flexibility to pivot based on emerging data and competitive dynamics.